Recent advances in pharmacotherapy of acute coronary syndrome
DOI:
https://doi.org/10.18203/2319-2003.ijbcp20163201Keywords:
ACS, Revascularization, Medical therapyAbstract
Acute coronary syndrome (ACS) describes the range of myocardial ischemic states that includes unstable angina, non-ST elevated myocardial infarction (MI), or ST-elevated MI. ACS is associated with substantial morbidity and mortality and places a large financial burden on the health care system. The diagnosis of ACS begins with a thorough clinical assessment of a patient’s presenting symptoms, electrocardiogram and cardiac troponin levels as well as a review of past medical history. Early risk stratification can assist clinicians in determining whether an early invasive management strategy or an initial conservative strategy should be pursued and can help determine appropriate pharmacologic therapies. Key components in the management of ACS include coronary revascularization when indicated; prompt initiation of dual antiplatelet therapy and anticoagulation; and consideration of adjuvant agents including beta blockers, inhibitors of the renin angiotensin system, and HmG-coenzyme A reductase inhibitors. It is essential for clinicians to take an individualized approach to treatment and consider long-term safety and efficacy when managing patients with a history of ACS after hospital discharge. This review identifies promising new or emerging techniques, as well as established tools, and reviews their current or potential role in clinical practice.
References
Nag T, Ghosh A. Cardiovascular disease risk factors in Asian Indian population: a systematic review. J Cardiovasc Dis Res. 2013;4(4):222-8.
Kumar A, Cannon CP. Acute coronary syndromes: diagnosis and management, part I . Mayo Clin Proc. 2009;84(10):917-38.
Puymirat E, Simon T, Steg PG, Schiele F, Guéret P, Blanchard D, et al. Association of changes in clinical characteristics and management with improvement in survival among patients with ST-elevation myocardial infarction. JAMA. 2012;308(10):998-100.
Roffi M, Patrono C, Collet JP, Mueller C. ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. European Heart Journal. 2015:1-59.
Cannon CP, Brindis RG, Chaitman BR, Cohen DJ. ACCF/AHA key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes and coronary artery disease. Circulation. 2013;127:1052-89.
Daga LC, Kaul U, Mansoor A. Approach to STEMI and NSTEMI. Supplement JAPI. 2011;59:19-25.
Chatterjee S, Chaudhuri D, Vedanthan R, Fuster V. Early intravenous beta-blockers in patients with acute coronary syndrome - a meta-analysis of randomized trials. Int J Cardiol. 2013;168(2):915-21.
Scottish Intercollegiate Guidelines Network (SIGN). Acute coronary syndrome. Edinburgh: SIGN; 2013. Available at URL: http://www.sign.ac.uk.
Acute coronary syndrome guideline, 2015. Available at http://www.worcsacute.nhs.uk.
Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352:1685-895.
Davì G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med. 2007;357:2482-94.
Jneid H, Bhatt DL, Corti R, Badimon JJ. Aspirin and Clopidogrel in Acute coronary syndromes therapeutic insights from the cure study free. Arch Intern Med. 2003;163(10):1145-53.
Acute coronary syndrome Management Strategies: Recent advances, 2014. Available at http://www.csi.org.in/Cardio_pdf/SEC_1/Ch-22.pdf.
Whellan DJ, Tricoci P, Chen E, Huang Z, Leibowitz DJ. Vorapaxar in acute coronary syndrome patients undergoing coronary artery bypass graft surgery: subgroup analysis from the TRACER trial. Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome. Am Coll Cardiol. 2014;63(11):1048-57.
Stone GW, Maehara A, Witzenbichler B, Godlewski J, Parise H, Dambrink JH, et al. Intracoronary abciximab and aspiration thrombectomy in patients with large anterior myocardial infarction. The INFUSE-AMI randomized trial. JAMA. 2012;307:1817-26.
Deibele AJ, Jennings LK, Tcheng JE, Neva C. Intracoronary eptibatide bolusadministration during percutaneous coronary revascularization for acute coronary syndromes with evaluation of platelet glycoprotein IIb/IIIa receptor occupancy and platelet function: the intracoronary eptibatide (ICE) trial. Circulation. 2010;121(6):784-91.
Hong MK. Recent advances in the treatment of ST-segment elevation myocardial infarction. Scientifica. 2012:1-13.
Amsterdam EA, Wenger NK, Brindis RG, Casey D. AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes: Executive Summary. J Am Coll Cardiol. 2014;64(24):2645-87.
Gretler DD, Guerciolini R, Williams PJ. Pharmacokinetic and pharmacodynamic properties of eptifibatide in subjects with normal or impaired renal function. Clin Ther. 2004;26:390-8.
Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD. ACC/AHA guideline update for the management of patients with unstable angina and non–ST-segment elevation myocardial infarction–2002: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Committee on the Management of Patients with Unstable Angina. Circulation. 2002;106:1893-1900.
Pollack CV. Anticoagulation in acute coronary syndrome and beyond. Available at http://www.emcreg.org/publications/monographs/2010/2010mono_cvp.pdf.
O’Gara PT, Kushner FG, Ascheim DD, Casey DE, Chung MK, de Lemos JA, et al. ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;61(4):78-140.
Bassand JP. The place of fondaparinux in the ESC and ACC/AHA guidelines for anticoagulation in patients with non-ST elevation acute coronary syndromes. European Heart Journal Supplements. 2008;10 (Supplement C):C22-29.
Spinler SA, de Denus S. Acute coronary syndrome. In: Joseph di Piro, Robert Talbet, Gary C Yee eds. Pharmacotherapy: A Pathophysiologic Approach. 9th ed. NY: Mc GrawHill; 2014:291-319.
Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). Circulation. 2004;110:588-636.
The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 1993;329:673-82.
Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145-53.
Pfeffer MA, McMurray JJV, Velazquez EJ, Rouleau JL, Køber L, Maggioni AP, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349:1893-906.
Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364:11-21.
Overbaugh KJ. Acute coronary syndrome. AJN. 2009;109(5):42-52.
Meine TJ, Roe MT, Chen AY, Patel MR, Washam JB. Association of intravenous morphine use and outcomes in acute coronary syndromes: results from the CRUSADE quality improvement initiative. Am Heart J. 2005;149:1043-9.
Welsford M, Nikolaou NI, Beygui F, Bossaert L, Ghaemmaghami C, Nonogi H, et al. Part 5: acute coronary syndromes: 2015 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science with Treatment Recommendations. Resuscitation. 2015;95:e121-46.
Tardif JC, Tanguay JF, Wright SR, Duchatelle V, Petroni T, Grégoire JC, et al. Effects of the P-selectin antagonist inclacumab on myocardial damage after percutaneous coronary intervention for non-ST-segment elevation myocardial infarction: results of the SELECT-ACS trial. J Am Coll Cardiol. 2013;61(20):2048-55.
Aggarwal B, Menon V. Recent advances in treatment of acute coronary syndromes. F1000 Prime Rep. 2013;5-56.
Romagnoli E, Biondi-Zoccai G, Sciahbasi A, Politi L, Rigattieri S, Pendenza G, et al. Radial versus femoral randomized investigation in ST-segment elevation acute coronary syndrome: the RIFLE-STEACS (Radial Versus Femoral Randomized Investigation in ST Elevation Acute Coronary Syndrome) study. J Am Coll Cardiol. 2012;60(24):2481-9.
Vlaar PJ, Svilaas T, van der Horst IC, Diercks GF, Fokkema ML, de Smet BJ, et al. Cardiac death and reinfarction after 1 year in the Thrombus Aspiration during Percutaneous coronary intervention in Acute myocardial infarction Study (TAPAS): a 1-year follow-up study. Lancet. 2008;371(9628):1915-20.
Sabate M, Cequier A, Iñiguez A, Serra A, Hernandez-Antolin R, Mainar V, et al. Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial infarction examination: 1 year results of a randomized controlled trial. Lancet. 2012;380(9852):1482-90.
Feres F, Costa RA, Bhatt DL, Leon MB, Botelho RV, King SB, et al. Optimized duration of clopidogrel therapy following treatment with the Endeavor zotarolimus-eluting stent in real-world clinical practice optimize trial: rationale and design of a large-scale, randomized, multicenter study. Am Heart J. 2012;164(6):810-6.e3.
Dewilde WJ, Oirbans T, Verheugt FW, Kelder JC, De Smet BJ, Herrman JP, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet. 2013;381(9872):1107-15.
O'Connor RE, Al Ali AS, Brady WJ, Ghaemmaghami CA, Menon V, Welsford M. Part 9: acute coronary syndromes: 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2015;132(suppl2):S483-S500.
